Rocket Pharmaceuticals Inc. has released its financial results for the first quarter ending March 31, 2025. The company reported a cash position, including cash, cash equivalents, and investments, totaling $318.2 million as of March 31, 2025. This robust financial status is expected to support operations into the fourth quarter of 2026. The company's research and development expenses for the quarter amounted to $35.9 million, reflecting a decrease from $45.2 million in the same period the previous year. This $9.3 million reduction was attributed to decreases in manufacturing and development costs, lab supplies, office expenses, compensation and benefits, and professional fees. In terms of operational updates, Rocket Pharmaceuticals is progressing with its Phase 2 pivotal study of RP-A501 for Danon disease, with a program update anticipated mid-year 2025. Additionally, initial data from the Phase 1 study of RP-A601 for PKP2-ACM is expected in May 2025. The company plans to submit an IND for the BAG3-DCM program by mid-year 2025. Sarbani Chaudhuri has been appointed as the Chief Commercial & Medical Affairs Officer, enhancing the company's leadership team. Rocket Pharmaceuticals continues to focus its resources on AAV cardiovascular programs, aiming to develop transformative therapies for patients with rare disorders.